Hope and help for your gastroparesis patients
Gastroparesis can be a frustrating condition to treat. But with Enterra™ Therapy, you can offer a minimally invasive, advanced treatment option in your patient’s journey to relief from nausea and vomiting.
Probable benefits backed by robust clinical science
Long-term studies show that diabetic and idiopathic gastroparesis patients receiving Enterra Therapy experienced significant improvements in symptoms.
Reduction in
median weekly vomiting1,2
87%
among idiopathic patients
Idiopathic group:
N=18, P<0.001
12 month follow-up
68%
among diabetic patients
Diabetic group:
N=36, P<0.001
12 month follow-up
Reduction in
hospitalization days1,2
100%
among idiopathic patients
Idiopathic group:
N=18, P<0.001
12 month follow-up
75%
among diabetic patients
Diabetic group:
N=39, P<0.001
12 month follow-up
High patient satisfaction3
80%
overall patient satisfaction with GES at 10 years
N=37
10 year follow-up
Target your patients’ nausea and vomiting symptoms
FDA-approved as a Humanitarian Device and supported by AGA and ACG guidelines, Enterra Therapy is the first and only device designed to reduce the nausea and vomiting associated with diabetic or idiopathic gastroparesis through gastric electrical stimulation (GES).
Find an implanter or GI specialist
More than 250 of the nation’s top medical centers implant Enterra Therapy.
If you have a patient who may be a candidate for receiving Enterra Therapy, use this tool to find a trained implanter or GI specialist in your area.
- McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. Neurogastroenterol Motil (2013) 25, 815–e636. *Manufacture sponsored study.
- McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010;8(11):947-e116. doi:10.1016/j.cgh.2010.05.020.
- Hedjoudje A, Huet E, Leroi AM, Desprez C, Melchior C, Gourcerol G. Efficacy of gastric electrical stimulation in intractable nausea and vomiting at 10 years: A retrospective analysis of prospectively collected data. Neurogastroenterol Motil. 2020;32(11):e13949. doi:10.1111/nmo.13949.
MKT-D-0006, Rev E
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?